We rank companies based on fund manager, research analyst and news sentiment
FOLD stock icon

Amicus Therapeutics
FOLD

$10.68
0.09%
 

About: Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Employees: 517

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

461% more call options, than puts

Call options by funds: $48.8M | Put options by funds: $8.71M

55% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 62

25% more capital invested

Capital invested by funds: $3.6B [Q3] → $4.52B (+$917M) [Q4]

14% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]

5.5% more ownership

Funds ownership: 103.13% [Q3] → 108.63% (+5.5%) [Q4]

9% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 33

1% less funds holding

Funds holding: 222 [Q3] → 219 (-3) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$15
40%
upside
Avg. target
$19
78%
upside
High target
$22
106%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
JP Morgan
Anupam Rama
78%upside
$19
Overweight
Maintained
18 Mar 2024
Cantor Fitzgerald
Kristen Kluska
106%upside
$22
Overweight
Reiterated
29 Feb 2024
Morgan Stanley
Jeffrey Hung
87%upside
$20
Overweight
Upgraded
19 Dec 2023
Morgan Stanley
Andrew Galler
40%upside
$15
Equal-Weight
Maintained
9 Nov 2023

Financial journalist opinion